NovaBio: Net profit in the third quarter is expected to increase by 100.56% to 180.78% year-on-year.

GoldenOctober2024

2024-10-07 08:07:04

Jinshi data news on October 7th, Notai Biology released performance forecast, it is expected that the net profit attributable to the owner of the parent company in the third quarter of 2024 will be 100 million to 140 million, an increase of 100.56% to 180.78% year-on-year. During the reporting period, the sales revenue of the company’s polypeptide bulk drugs increased significantly compared to the same period last year.

View Original

Disclaimer: The information on this page may come from third parties and does not represent the views or opinions of Gate. The content displayed on this page is for reference only and does not constitute any financial, investment, or legal advice. Gate does not guarantee the accuracy or completeness of the information and shall not be liable for any losses arising from the use of this information. Virtual asset investments carry high risks and are subject to significant price volatility. You may lose all of your invested principal. Please fully understand the relevant risks and make prudent decisions based on your own financial situation and risk tolerance. For details, please refer to Disclaimer.

Comment

0/400

No comments